The Ten-Year Plan: How Sandoz Sees GLP-1s Shaping Up

CEO Richard Saynor Also Talks ADCs, Oligonucleotides And Value Added Medicines

 
• By Dave Wallace
  
Richard Saynor sets out the road to 2035 for GLP-1s (Shutterstock)

More from Strategy

More from Leadership